相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overview of Myeloproliferative Neoplasms History, Pathogenesis, Diagnostic Criteria, and Complications
Douglas Tremblay et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2021)
Supercharging BRD4 with NUT in carcinoma
Kyle P. Eagen et al.
ONCOGENE (2021)
Modulation of BRD4 in HIV epigenetic regulation: implications for finding an HIV cure
Edrous Alamer et al.
RETROVIROLOGY (2021)
Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
Yanli Sun et al.
FRONTIERS IN PHARMACOLOGY (2021)
Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
Pan Tang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
Peter S. Dragovich et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
Peter S. Dragovich et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Helen E. Aylott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Achieving clinical success with BET inhibitors as anti-cancer agents
Tatiana Shorstova et al.
BRITISH JOURNAL OF CANCER (2021)
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection
Richard J. Mills et al.
CELL (2021)
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
Gregory G. Schwartz et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Hypertranscription and replication stress in cancer
Akhil Bowry et al.
TRENDS IN CANCER (2021)
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook et al.
CLINICAL CANCER RESEARCH (2020)
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Thomas H. Pillow et al.
CHEMMEDCHEM (2020)
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
Emily J. Faivre et al.
NATURE (2020)
Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites
Michael D. Olp et al.
ACS CHEMICAL BIOLOGY (2020)
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Omer Gilan et al.
SCIENCE (2020)
Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain
George S. Sheppard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation
Zhiqing Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
Shaokun Shu et al.
MOLECULAR CELL (2020)
Domain-selective targeting of BET proteins in cancer and immunological diseases
Massimo Petretich et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2020)
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer
P. Jake Slavish et al.
CANCER RESEARCH (2020)
Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?
Ian J. Groves et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins
Alex Preston et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins
Robert J. Watson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype
Christopher R. Wellaway et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
Malaka Ameratunga et al.
BRITISH JOURNAL OF CANCER (2020)
Proteolysis-targeting chimaeras mediated the degradation of bromodomain and extra-terminal domain proteins
Yifei Yang et al.
FUTURE MEDICINAL CHEMISTRY (2020)
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family
Alex Preston et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies
Angela Su et al.
CANCER DISCOVERY (2020)
Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer
Francisco J. Cimas et al.
PHARMACEUTICS (2020)
A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103)
Christine Lihou et al.
BLOOD (2020)
The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+Hematopoietic Stem Cells
Jennifer A. Mertz et al.
BLOOD (2020)
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
Sarina A. Piha-Paul et al.
JNCI CANCER SPECTRUM (2020)
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
Sophie Postel-Vinay et al.
EUROPEAN JOURNAL OF CANCER (2019)
BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer
Daniel J. Coleman et al.
ONCOGENE (2019)
Bromodomains: a new target class for drug development
Andrea G. Cochran et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
BET Bromodomain Inhibitor iBET151 Impedes Human ILC2 Activation and Prevents Experimental Allergic Lung Inflammation
Bernhard Kerscher et al.
FRONTIERS IN IMMUNOLOGY (2019)
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
Kausik K. Ray et al.
AMERICAN HEART JOURNAL (2019)
MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or Add-on to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis
John Mascarenhas et al.
BLOOD (2019)
GNE-0011, a novel monovalent BRD4 degrader
Robert A. Blake
CANCER RESEARCH (2019)
41OA phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma
K A Blum et al.
ANNALS OF ONCOLOGY (2018)
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms (vol 33, pg 29, 2018)
Maria Kleppe et al.
CANCER CELL (2018)
BET'ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms
Qingfei Jiang et al.
CANCER CELL (2018)
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
Jonathan Welti et al.
CLINICAL CANCER RESEARCH (2018)
Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation
Zhiqing Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
Chong Qin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Plasticity in binding confers selectivity in ligand-induced protein degradation
Radoslaw P. Nowak et al.
NATURE CHEMICAL BIOLOGY (2018)
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML
Daniel Gerlach et al.
ONCOGENE (2018)
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
A. Esteve-Arenys et al.
ONCOGENE (2018)
Selective Antagonists of the Bronchiolar Epithelial NF-κB-Bromodomain-Containing Protein 4 Pathway in Viral-Induced Airway Inflammation
Bing Tian et al.
CELL REPORTS (2018)
DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4
Xin Jin et al.
MOLECULAR CELL (2018)
The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer
Yufang Ma et al.
CLINICAL CANCER RESEARCH (2017)
Drug Discovery Targeting Bromodomain-Containing Protein 4
Zhiqing Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor
Keith F. McDaniel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer
Liang Ouyang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
BRD4 Couples NF-κB/RelA with Airway Inflammation and the IRF-RIG-I Amplification Loop in Respiratory Syncytial Virus Infection
Bing Tian et al.
JOURNAL OF VIROLOGY (2017)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
Xiangpeng Dai et al.
NATURE MEDICINE (2017)
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation
Pingzhao Zhang et al.
NATURE MEDICINE (2017)
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
Hana Janouskova et al.
NATURE MEDICINE (2017)
Click chemistry enables preclinical evaluation of targeted epigenetic therapies
Dean S. Tyler et al.
SCIENCE (2017)
Management of myelofibrosis: JAK inhibition and beyond
Maximilian Stahl et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Targeting Cancer Cells with BET Bromodomain Inhibitors
Yali Xu et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Novel Therapies for Myelofibrosis
Kristen Pettit et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
Neel Shah et al.
ELIFE (2017)
Clinical Correlates and Prognostic Significance of IL-8, sIL-2R, and Immunoglobulin-Free Light Chain Levels in Patients with Myelofibrosis
Maria V. Barabanshikova et al.
ONCOLOGY RESEARCH AND TREATMENT (2017)
BET inhibitors: a novel epigenetic approach
D. B. Doroshow et al.
ANNALS OF ONCOLOGY (2017)
The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
Yasushi Taniguchi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxylethy]-1,3-dimethyl-piperazin-2-one (AZD5153)
Robert H. Bradbury et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu et al.
NATURE (2016)
Potent and selective bivalent inhibitors of BET bromodomains
Michael J. Waring et al.
NATURE CHEMICAL BIOLOGY (2016)
Design and characterization of bivalent BET inhibitors
Minoru Tanaka et al.
NATURE CHEMICAL BIOLOGY (2016)
Epigenetic drug discovery: breaking through the immune barrier
David F. Tough et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Bromodomains: Translating the words of lysine acetylation into myelin injury and repair
Achilles Ntranos et al.
NEUROSCIENCE LETTERS (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Anastasios Stathis et al.
CANCER DISCOVERY (2016)
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
Alison M. Kurimchak et al.
Cell Reports (2016)
High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML
Yue Zhao et al.
CELL REPORTS (2016)
Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer
Fade Gong et al.
PLOS GENETICS (2016)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim et al.
LANCET HAEMATOLOGY (2016)
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Michael Zengerle et al.
ACS CHEMICAL BIOLOGY (2015)
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert et al.
NATURE (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
BRD4 is a novel therapeutic target for liver fibrosis
Ning Ding et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Regulation of NO Synthesis, Local Inflammation, and Innate Immunity to Pathogens by BET Family Proteins
Sebastian Wienerroither et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms
B. S. Wyspianska et al.
LEUKEMIA (2014)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
Michele Ceribelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
Jessica E. Bolden et al.
CELL REPORTS (2014)
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
Bjoern Chapuy et al.
CANCER CELL (2013)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses
Anna C. Belkina et al.
JOURNAL OF IMMUNOLOGY (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Panagis Filippakopoulos et al.
CELL (2012)
Functional genomics identifies therapeutic targets for MYC-driven cancer
Masafumi Toyoshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Double Bromodomain-Containing Gene Brd2 Is Essential for Embryonic Development in Mouse
Enyuan Shang et al.
DEVELOPMENTAL DYNAMICS (2009)
The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription
Gary LeRoy et al.
MOLECULAR CELL (2008)
Structure and acetyl-lysine recognition of the bromodomain
S. Mujtaba et al.
ONCOGENE (2007)
Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4
D Houzelstein et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
分享论文
